X

ULTIVA FOR INJECTION 1mg/VIAL

Product Information

Registration Status: Active

SIN09542P

ULTIVA FOR INJECTION 1mg/VIAL is approved to be sold in Singapore with effective from 1997-11-21. It is marketed by DCH AURIGA SINGAPORE, with the registration number of SIN09542P.

This product contains Remifentanil 1mg/vial in the form of INJECTION, POWDER, FOR SOLUTION. It is approved for INTRAVENOUS use.

This product is manufactured by GlaxoSmithKline Manufacturing S.p.A. in ITALY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.

Indication

For use during the induction and maintenance of general anesthesia.

Mechanism of Action

Remifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.

Clearance

* 40 mL/min/kg [young, healthy adults]

Active Ingredient/Synonyms

REMIFENTANIL | Remifentanyl | Remifentanil |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!